Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma

November 25, 2020

A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue. The results suggest that CAR T cells should be further evaluated as treatments for neuroblastoma and other solid tumors, which have typically been difficult to target with T cell therapies. CAR T cells are immune cells from patients that have been engineered to hunt down cancer cells, and have shown great promise against blood cancers such as leukemia. However, it has been much more difficult to use CAR T cells against solid tumors, which are harder for the cells to penetrate. Here, Karin Straathof and colleagues performed a phase 1 trial to study the safety and performance of CAR T cells against neuroblastoma. They created CAR T cells that target the GD2 protein, which is common on neuroblastoma tumors, and administered the cells to 12 pediatric patients who had failed to respond to standard chemotherapies. None of the children showed measurable drops in the size of their tumors after one month, according to standard X-ray criteria, and some experienced immune-related side effects. However, three patients who also received two conditioning drugs showed some signs of antitumor immunity, and did not display any signs of damage to healthy nerve tissue bearing GD2. Straathof et al. note that further modifications to the CAR T cells will be necessary to boost their persistence within tumors, given the transient nature of the observed antitumor responses.
-end-


American Association for the Advancement of Science

Related Neuroblastoma Articles from Brightsurf:

Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.

Researchers mine data and connect the dots about processes driving neuroblastoma
St. Jude Children's Research Hospital scientists lead genome analysis to better understand one of the most common childhood solid tumors.

Promising treatment for aggressive childhood cancer
A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer.

MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma
The researchers adopted the functional polymorphism research strategy to screen out the functional polymorphisms associated with neuroblastoma in Chinese population and elucidate its mechanism, providing data on children susceptible to neuroblastoma in China.

A novel radioisotope therapy for children with neuroblastoma
Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital.

New method for monitoring residual disease after treatment in children with neuroblastoma
Neuroblastoma is a cancer that affects children, characterized by solid tumors that develop from immature nerve cells.

Research sheds important light on the metastasis of neuroblastoma
Research sheds important light on the metastasis of neuroblastoma.

A step forward in the struggle against neuroblastoma, a type of childhood cancer
A protein called CD44 makes it possible to identify the population of mother cells that are responsible for the aggressive nature and low survival rate of neuroblastoma, a type of childhood cancer that mainly affects children of two and three years old.

More children survive neuroblastoma
Both the survival rate and the incidence of neuroblastoma have increased in the last decennia in the Netherlands, as was shown by a study from the Princess Máxima Center.

TTUHSC researchers publish preclinical data on new drug combination to treat neuroblastoma
Neuroblastoma, the most common cancer outside of the brain in infants and young children, often fails to respond to therapy.

Read More: Neuroblastoma News and Neuroblastoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.